Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study

BACKGROUND: Efficacy, safety and pharmacokinetics of simeprevir (TMC435), a once-daily, noncovalent, oral hepatitis C virus (HCV) NS3/4A protease inhibitor, was evaluated in combination with peginterferon α-2a/ribavirin (PegIFNα-2a/RBV) for treatment-naïve, HCV genotype 1-infected patients in Japan....

Descripción completa

Detalles Bibliográficos
Autores principales: Hayashi, Norio, Seto, Chiharu, Kato, Mai, Komada, Yuji, Goto, Shoichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2013
Materias:
Original Article—LIVER, PANCREAS, AND BILIARY TRACT
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895197/
https://www.ncbi.nlm.nih.gov/pubmed/24005956
http://dx.doi.org/10.1007/s00535-013-0875-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895197/
https://www.ncbi.nlm.nih.gov/pubmed/24005956
http://dx.doi.org/10.1007/s00535-013-0875-1

Ejemplares similares